Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SOHO State of the Art Updates and Next Questions | Implementing Next-Generation Sequencing (NGS) in Resource-Constrained Settings: The Experience of the International Consortium on Acute Leukemias (ICAL).

Clinical lymphoma, myeloma & leukemia·2026

Same author

Evaluating Risk Factors for Early Mortality in Adult ALL in Brazil.

JCO global oncology·2026

Same author

ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia.

Cell reports. Medicine·2026

Same author

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Challenges in evaluating thromboembolic risk in acute leukemia: clinical profiling and limitations of current scoring systems.

Research and practice in thrombosis and haemostasis·2025

Same author

High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability.

Signal transduction and targeted therapy·2025

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Targeting the acute myeloid leukemia stem cells.

Alexandre Krause¹, M Luciana, Fontanari Krause

¹Hematology Division, Department of Internal Medicine, Medical School of Ribeirão Preto and National Institute of Science and Technology on Cell Based Therapy, University of São Paulo, Campus USP, Ribeirão Preto, SP, Brazil.

Anti-Cancer Agents in Medicinal Chemistry

|February 27, 2010

Summary

Leukemia stem cells (LSCs) are immature, chemotherapy-resistant cells that drive cancer. Targeting LSCs

More Related Videos

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Experiment Videos

Last Updated: Jun 15, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Area of Science:

Hematology
Cancer Biology
Stem Cell Research

Background:

The concept of leukemia stem cells (LSCs) as a distinct, therapy-resistant subpopulation within leukemic bulk is established.
LSCs share self-renewal and quiescence properties with normal hematopoietic stem cells (HSCs) but possess unique survival mechanisms.
Acute myeloid leukemia (AML) serves as a model for understanding LSC biology and therapeutic targeting.

Purpose of the Study:

To review the survival mechanisms employed by leukemia stem cells (LSCs).
To discuss potential therapeutic strategies for eradicating LSCs in acute myeloid leukemia (AML).
To highlight the unique characteristics of LSCs compared to normal HSCs and differentiated leukemic cells.

Main Methods:

Review of existing literature on leukemia stem cell biology.
Analysis of LSC-specific pathways regulating apoptosis, cell cycle, and telomere maintenance.
Characterization of LSC interactions with the tumor microenvironment.

Main Results:

LSCs exhibit distinct pathway dysregulation (apoptosis, cell cycle, telomere maintenance, transport pumps) compared to normal HSCs and other leukemic cells.
Unique interactions between LSCs and their microenvironment contribute to their survival.
Therapeutic strategies targeting LSC-specific features show promising preclinical and early clinical results.

Conclusions:

Understanding LSC biology is crucial for developing effective AML treatments.
Targeting LSC-specific vulnerabilities offers a promising avenue for achieving durable remissions.
Further research into LSC-microenvironment interactions may reveal novel therapeutic targets.